MMRF CoMMpassSM Study

For Clinicians

Why become a CoMMpass study investigator? There are so many good reasons.
CoMMpass will collect clinical and molecular profiling data on 1000 newly diagnosed patients.
Sundar Jagannath

Sundar Jagannath, MD
CoMMpass™ Investigator
ELIGIBILITY: CoMMpass enrolls newly diagnosed symptomatic multiple myeloma patients within 30 days prior to initiating therapy for the disease.


  • Male or female 18 years or older
  • Symptomatic multiple myeloma with measurable disease that includes at least one of the following:

    - Serum M protein ≥1 g/dL

    - Urine M protein ≥ 200 mg/24 hr

    - Involved free light chain level >10 mg/dL and an abnormal serum free   light chain ratio (<0.26 or >1.65)

    - Candidate for systemic therapy that includes an IMid® (eg, lenalidomide,   pomalidomide, or thalidomide) and/or a proteasome inhibitor as part of the initial regimen

    - No more than 30 days from baseline bone marrow evaluation to initiation of therapy

    - Be able to read, understand, and sign the Informed Consent document


  • Currently receiving systemic therapy for multiple myeloma.
    Please note that a single dose of bisphosphonates and up to 100 mg total dose of
    dexamethasone or equivalent corticosteroids are permitted prior to study registration
  • Prior (within the last 5 years) malignancy.
    Exceptions include basal or squamous cell carcinoma or in situ cancers of the cervix
  • Enrollment in a blinded clinical trial for the first-line treatment of multiple myeloma. Patients may be enrolled in subsequent clinical trials as long as continued access to data and tissue, as per this protocol, is not prohibited


Information for Patients »

Watch Videos about CoMMpass »

Read News Articles about CoMMpass »
Email the MMRF About Enrolling Your Patients
Contact the MMRF today to learn more about having your patients participate in the CoMMpass study.
Call Now
Watch video from Principal Investigator
Sagar Lonial, MD of Winship Cancer Institute of Emory University and MMRF CoMMpass Study Principal Investigator speaks about the importance of participating in this study.
Find a Site